Belite Bio to Participate in the Leerink Partners Global Biopharma Conference

Rhea-AI Summary

Belite Bio, Inc. (BLTE) to participate in Leerink Partners Global Biopharma Conference, hosting a fireside chat on degenerative retinal diseases. Webcast available on the company's website.

SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in the Leerink Partners Global Biopharma Conference being held in Miami, FL, on March 11-13, 2024. The Company will host a fireside chat on Wednesday, March 13, 2024, at 10:00 am ET.

A webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replay will be archived for 90 days following the presentation date.

About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at www.belitebio.com.

Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com

Julie Fallon
belite@argotpartners.com

When will Belite Bio, Inc. participate in the Leerink Partners Global Biopharma Conference?

Belite Bio, Inc. will participate in the Leerink Partners Global Biopharma Conference on March 11-13, 2024.

What is the focus of Belite Bio, Inc. in drug development?

Belite Bio, Inc. focuses on advancing novel therapeutics targeting degenerative retinal diseases with significant unmet medical needs.

Where can the webcast of the fireside chat be accessed?

The webcast of the fireside chat can be accessed under the 'Events' tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events.

How long will the replay of the fireside chat be archived?

The replay will be archived for 90 days following the presentation date.